Common Contracts
2 similar Collaboration and License Agreement contracts by ADC Therapeutics SA
THIRD AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT BETWEEN ADC THERAPEUTICS SA AND GENMAB A/SCollaboration and License Agreement • September 21st, 2020 • ADC Therapeutics SA • Pharmaceutical preparations
THIS THIRD AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT (“Third Amendment”) made and entered into, effective as of June 24, 2020 (“Amendment Effective Date”), amends that certain COLLABORATION AND LICENSE AGEEMENT entered into by and between ADC Therapeutics SA, a Swiss Corporation, having its principal place of business at Biopole, rte de la Corniche 3B, 1066 Epalinges, Switzerland (formerly ADC Therapeutics Sarl) and its Affiliates (“ADCT”), and GENMAB A/S a Danish corporation, having its principal place of business at Kalvebod Brygge 43, 1560 Copenhagen V, Denmark, CVR no. 2102 3884 (“Genmab”) on 14 June 2013, as amended (“Agreement”). Genmab and ADCT are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
THIRD AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT BETWEEN ADC THERAPEUTICS SA AND GENMAB A/SCollaboration and License Agreement • September 11th, 2020 • ADC Therapeutics SA • Pharmaceutical preparations
THIS THIRD AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT (“Third Amendment”) made and entered into, effective as of June 24, 2020 (“Amendment Effective Date”), amends that certain COLLABORATION AND LICENSE AGEEMENT entered into by and between ADC Therapeutics SA, a Swiss Corporation, having its principal place of business at Biopole, rte de la Corniche 3B, 1066 Epalinges, Switzerland (formerly ADC Therapeutics Sarl) and its Affiliates (“ADCT”), and GENMAB A/S a Danish corporation, having its principal place of business at Kalvebod Brygge 43, 1560 Copenhagen V, Denmark, CVR no. 2102 3884 (“Genmab”) on 14 June 2013, as amended (“Agreement”). Genmab and ADCT are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
